Therefore, it remains unclear whether DPP-4 inhibitors slow the process of atherosclerosis directly via the improvement of hyperglycemia and related AGE formation, indirectly via the amelioration of comorbid risk factors, or through the pleiotropic effects of incretins. The gene discussed is DPP4; the disease is Hyperglycemia.